INTS2

Summary

INTS2 (integrator complex subunit 2, HGNC:29241) is a protein-coding gene on chromosome 17q23.2, encoding Integrator complex subunit 2 (Q9H0H0). Component of the integrator complex, a multiprotein complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes. It is a common-essential gene (DepMap: required in 93.9% of cancer cell lines).

INTS2 is a subunit of the Integrator complex, which associates with the C-terminal domain of RNA polymerase II large subunit (POLR2A; MIM 180660) and mediates 3-prime end processing of small nuclear RNAs U1 (RNU1; MIM 180680) and U2 (RNU2; MIM 180690) (Baillat et al., 2005 [PubMed 16239144]).

Source: NCBI Gene 57508 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 159 total — 1 pathogenic
• Cancer dependency (DepMap): dependent in 93.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_001351695

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29241
Approved symbol	INTS2
Name	integrator complex subunit 2
Location	17q23.2
Locus type	gene with protein product
Status	Approved
Aliases	INT2
Ensembl gene	ENSG00000108506
Ensembl biotype	protein_coding
OMIM	611346
Entrez	57508

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 15 protein_coding, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000251334, ENST00000444766, ENST00000578805, ENST00000583076, ENST00000583822, ENST00000584967, ENST00000646745, ENST00000646954, ENST00000647009, ENST00000866719, ENST00000866720, ENST00000866721, ENST00000913652, ENST00000913653, ENST00000913654, ENST00000913655, ENST00000913656, ENST00000963385, ENST00000963386

RefSeq mRNA: 3 — MANE Select: NM_001351695 NM_001330417, NM_001351695, NM_020748

CCDS: CCDS45750, CCDS82181

Canonical transcript exons

ENST00000251334 — 25 exons

Exon	Start	End
ENSE00000740937	61867833	61868009
ENSE00000740958	61889786	61889894
ENSE00000740960	61891513	61891689
ENSE00000740964	61893765	61893899
ENSE00000740967	61895315	61895383
ENSE00000740969	61897469	61897583
ENSE00000740971	61897668	61897739
ENSE00000820448	61924961	61925099
ENSE00000925253	61904460	61904585
ENSE00000925254	61907408	61907634
ENSE00000925255	61911520	61911693
ENSE00000925256	61911940	61912070
ENSE00000925257	61919400	61919513
ENSE00000925258	61921725	61921827
ENSE00001113076	61872265	61872460
ENSE00001113077	61869273	61869380
ENSE00001113078	61869034	61869139
ENSE00001113079	61869737	61869988
ENSE00003498879	61884901	61885005
ENSE00003550261	61874913	61875038
ENSE00003566340	61926352	61926662
ENSE00003583309	61877887	61878088
ENSE00003651910	61881007	61881171
ENSE00003737481	61865367	61867726
ENSE00003819457	61927654	61927982

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 94.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.1817 / max 143.5361, expressed in 1733 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
167408	8.8926	1688
167407	1.6890	941
167409	0.6001	319

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	94.39	gold quality
endothelial cell	CL:0000115	84.23	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.63	gold quality
middle temporal gyrus	UBERON:0002771	82.30	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.20	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.17	gold quality
esophagus squamous epithelium	UBERON:0006920	81.89	gold quality
calcaneal tendon	UBERON:0003701	81.80	gold quality
germinal epithelium of ovary	UBERON:0001304	80.56	gold quality
epithelial cell of pancreas	CL:0000083	79.96	gold quality
tibia	UBERON:0000979	79.96	gold quality
ventricular zone	UBERON:0003053	79.81	gold quality
islet of Langerhans	UBERON:0000006	79.68	gold quality
caput epididymis	UBERON:0004358	79.57	gold quality
adrenal tissue	UBERON:0018303	79.37	gold quality
mucosa of paranasal sinus	UBERON:0005030	78.87	gold quality
bone marrow cell	CL:0002092	78.82	gold quality
colonic epithelium	UBERON:0000397	78.60	gold quality
cauda epididymis	UBERON:0004360	78.59	gold quality
visceral pleura	UBERON:0002401	78.54	gold quality
epithelium of nasopharynx	UBERON:0001951	78.53	gold quality
oral cavity	UBERON:0000167	78.33	gold quality
fallopian tube	UBERON:0003889	78.21	gold quality
gingival epithelium	UBERON:0001949	78.08	gold quality
primary visual cortex	UBERON:0002436	78.08	gold quality
parietal pleura	UBERON:0002400	78.06	gold quality
corpus callosum	UBERON:0002336	77.77	gold quality
cerebellar cortex	UBERON:0002129	77.67	gold quality
cerebellar hemisphere	UBERON:0002245	77.65	gold quality
gingiva	UBERON:0001828	77.32	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.62
E-CURD-10	no	374.81
E-MTAB-6386	no	372.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

114 targeting INTS2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-146A-5P	99.96	68.93	988

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 93.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 1)

• Mutation in INTS2 gene is associated with gastric cancer peritoneal carcinomatosis. (PMID:26811494)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ints2	ENSDARG00000069085
mus_musculus	Ints2	ENSMUSG00000018068
rattus_norvegicus	Brip1	ENSRNOG00000059997
drosophila_melanogaster	IntS2	FBGN0030858
caenorhabditis_elegans		WBGENE00013877

Protein

Protein identifiers

Integrator complex subunit 2 — Q9H0H0 (reviewed: Q9H0H0)

All UniProt accessions (5): Q9H0H0, A0A2R8Y4Z6, A0A2R8Y7F8, J3KMZ7, J3KRH0

UniProt curated annotations — full annotation on UniProt →

Function. Component of the integrator complex, a multiprotein complex that terminates RNA polymerase II (Pol II) transcription in the promoter-proximal region of genes. The integrator complex provides a quality checkpoint during transcription elongation by driving premature transcription termination of transcripts that are unfavorably configured for transcriptional elongation: the complex terminates transcription by (1) catalyzing dephosphorylation of the C-terminal domain (CTD) of Pol II subunit POLR2A/RPB1 and SUPT5H/SPT5, (2) degrading the exiting nascent RNA transcript via endonuclease activity and (3) promoting the release of Pol II from bound DNA. The integrator complex is also involved in terminating the synthesis of non-coding Pol II transcripts, such as enhancer RNAs (eRNAs), small nuclear RNAs (snRNAs), telomerase RNAs and long non-coding RNAs (lncRNAs). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the integrator complex.

Subunit / interactions. Component of the Integrator complex, composed of core subunits INTS1, INTS2, INTS3, INTS4, INTS5, INTS6, INTS7, INTS8, INTS9/RC74, INTS10, INTS11/CPSF3L, INTS12, INTS13, INTS14 and INTS15. The core complex associates with protein phosphatase 2A subunits PPP2CA and PPP2R1A, to form the Integrator-PP2A (INTAC) complex.

Subcellular location. Nucleus. Nucleus membrane. Cytoplasm.

Similarity. Belongs to the Integrator subunit 2 family.

RefSeq proteins (3): NP_001317346, NP_001338624, NP_065799 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026236	Int2_metazoa	Family
IPR029321	INTS2	Family

Pfam: PF14750

UniProt features (93 total): helix 74, strand 9, turn 7, chain 1, transmembrane region 1, sequence variant 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
8RC4	ELECTRON MICROSCOPY	3.1
7CUN	ELECTRON MICROSCOPY	3.5
7PKS	ELECTRON MICROSCOPY	3.6
8RBZ	ELECTRON MICROSCOPY	3.7
8RBX	ELECTRON MICROSCOPY	4.1
8YJB	ELECTRON MICROSCOPY	4.1
7YCX	ELECTRON MICROSCOPY	4.18
9VD9	ELECTRON MICROSCOPY	4.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H0H0-F1	78.90	0.27

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6807505	RNA polymerase II transcribes snRNA genes
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 134 (showing top): GOBP_MACROMOLECULE_CATABOLIC_PROCESS, ATGTTAA_MIR302C, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, GOBP_RNA_SURVEILLANCE, MODULE_285, TGCTGAY_UNKNOWN, ATTCTTT_MIR186, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GARY_CD5_TARGETS_DN, GOBP_TRANSCRIPTION_INITIATION_AT_RNA_POLYMERASE_II_PROMOTER, ATCATGA_MIR433, ZHANG_BREAST_CANCER_PROGENITORS_UP, GOBP_SNRNA_PROCESSING, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION

GO Biological Process (4): snRNA processing (GO:0016180), regulation of transcription elongation by RNA polymerase II (GO:0034243), snRNA 3’-end processing (GO:0034472), RNA polymerase II transcription initiation surveillance (GO:0160240)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), membrane (GO:0016020), nuclear membrane (GO:0031965), integrator complex (GO:0032039), INTAC complex (GO:0160232)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
nuclear protein-containing complex	2
RNA processing	1
snRNA metabolic process	1
transcription elongation by RNA polymerase II	1
regulation of DNA-templated transcription elongation	1
snRNA processing	1
RNA 3’-end processing	1
transcription initiation at RNA polymerase II promoter	1
nuclear RNA surveillance	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
nucleus	1
nuclear envelope	1
organelle membrane	1
integrator complex	1

Protein interactions and networks

STRING

2024 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
INTS2	INTS11	Q5TA45	913
INTS2	INTS1	Q8N201	897
INTS2	INTS5	Q6P9B9	874
INTS2	INTS4	Q96HW7	831
INTS2	INTS8	Q75QN2	799
INTS2	INTS3	Q68E01	775
INTS2	INTS6	Q9UL03	724
INTS2	INTS9	Q9NV88	719
INTS2	INTS7	Q9NVH2	713
INTS2	INTS12	Q96CB8	665
INTS2	INTS13	Q9NVM9	664
INTS2	INTS10	Q9NVR2	606
INTS2	MED13	Q9UHV7	557
INTS2	POLR2A	P24928	548
INTS2	CHCT1	Q86WR6	546

IntAct

120 interactions, top by confidence:

A	B	Type	Score
PPP2R1A	STRN	psi-mi:“MI:0914”(association)	0.880
POLR2C	SUPT5H	psi-mi:“MI:0914”(association)	0.640
SCN2B	EXOC5	psi-mi:“MI:0914”(association)	0.640
VSIG1	TTI1	psi-mi:“MI:0914”(association)	0.640
GYPA	TCAF2	psi-mi:“MI:0914”(association)	0.640
CCDC57	INTS2	psi-mi:“MI:0915”(physical association)	0.560
INTS2	DEF6	psi-mi:“MI:0915”(physical association)	0.560
NCK2	INTS2	psi-mi:“MI:0915”(physical association)	0.560
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
SLC15A1	METTL15	psi-mi:“MI:0914”(association)	0.530
CD274	TTI1	psi-mi:“MI:0914”(association)	0.530
SUPT5H	POLR2D	psi-mi:“MI:0914”(association)	0.530
TMEM9	ESYT2	psi-mi:“MI:0914”(association)	0.530
DPEP1	ILVBL	psi-mi:“MI:0914”(association)	0.530
CD70	METTL15	psi-mi:“MI:0914”(association)	0.530
VSIG1	TNPO2	psi-mi:“MI:0914”(association)	0.530
STK16	UNC119B	psi-mi:“MI:0914”(association)	0.530
ILVBL	SLC33A1	psi-mi:“MI:0914”(association)	0.530
APLNR	SLC33A1	psi-mi:“MI:0914”(association)	0.530
CD40	EXOC5	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
P2RY10	ATM	psi-mi:“MI:0914”(association)	0.530
TGOLN2	DENND11	psi-mi:“MI:0914”(association)	0.530

BioGRID (141): INTS2 (Affinity Capture-MS), INTS2 (Affinity Capture-MS), INTS2 (Affinity Capture-MS), INTS2 (Affinity Capture-MS), INTS2 (Affinity Capture-MS), ABCF3 (Co-fractionation), C7orf26 (Co-fractionation), INTS1 (Co-fractionation), INTS2 (Co-fractionation), INTS2 (Co-fractionation), INTS2 (Co-fractionation), INTS2 (Co-fractionation), RPP30 (Co-fractionation), INTS2 (Proximity Label-MS), INTS2 (Affinity Capture-MS)

ESM2 similar proteins: A1Z8X3, A1ZAK1, G5ED39, H2QII6, O01510, O08662, O94668, P42173, P42286, P49792, Q00416, Q03280, Q0IEK6, Q10573, Q10669, Q13535, Q18508, Q18892, Q196Z9, Q29L39, Q2U639, Q5EAK6, Q5EB59, Q5RIW8, Q5ZKU4, Q61CW2, Q61WP7, Q6CP76, Q6CT34, Q6V3W0, Q70PP2, Q751J3, Q756G2, Q75DV4, Q80YQ2, Q8IRS9, Q8IRT0, Q9DE14, Q9GNN7, Q9H0H0

Diamond homologs: Q5ZKU4, Q80UK8, Q9H0H0, Q9VX31

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
INTS2	“form complex”	“Integrator complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 142 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
FGFR2 mutant receptor activation	6	49.1×	1e-07
Signaling by FGFR2 IIIa TM	6	38.8×	3e-07
Abortive elongation of HIV-1 transcript in the absence of Tat	7	37.4×	5e-08
Pausing and recovery of Tat-mediated HIV elongation	8	31.7×	3e-08
Tat-mediated HIV elongation arrest and recovery	8	31.7×	3e-08
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	7	30.7×	1e-07
Signaling by FGFR2	7	30.7×	1e-07
RNA Pol II CTD phosphorylation and interaction with CE	7	30.7×	1e-07

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of cytosolic calcium ion concentration	9	8.6×	5e-04
G protein-coupled receptor signaling pathway	16	4.7×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

159 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	126
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2685605	GRCh37/hg19 17q23.2(chr17:59960921-60036130)x1	Pathogenic

SpliceAI

4450 predictions. Top by Δscore:

Variant	Effect	Δscore
17:61867724:GACC:G	acceptor_loss	1.0000
17:61867725:ACC:A	acceptor_loss	1.0000
17:61867727:C:CC	acceptor_gain	1.0000
17:61867728:T:A	acceptor_loss	1.0000
17:61867828:CTTA:C	donor_loss	1.0000
17:61867830:TACGT:T	donor_loss	1.0000
17:61867831:A:AC	donor_gain	1.0000
17:61867831:A:C	donor_loss	1.0000
17:61867832:C:CC	donor_gain	1.0000
17:61867832:CG:C	donor_gain	1.0000
17:61868005:TAAAA:T	acceptor_gain	1.0000
17:61868006:AAAA:A	acceptor_gain	1.0000
17:61868007:AAA:A	acceptor_gain	1.0000
17:61868008:AA:A	acceptor_gain	1.0000
17:61868009:AC:A	acceptor_loss	1.0000
17:61868010:C:CC	acceptor_gain	1.0000
17:61868011:T:G	acceptor_loss	1.0000
17:61869756:G:C	donor_gain	1.0000
17:61869813:A:C	donor_gain	1.0000
17:61869816:T:TA	donor_gain	1.0000
17:61869849:T:TA	donor_gain	1.0000
17:61869858:C:A	donor_gain	1.0000
17:61869890:TTGA:T	donor_gain	1.0000
17:61869904:A:C	donor_gain	1.0000
17:61869984:CTATC:C	acceptor_gain	1.0000
17:61869985:TATC:T	acceptor_gain	1.0000
17:61869987:TC:T	acceptor_gain	1.0000
17:61869987:TCC:T	acceptor_loss	1.0000
17:61869988:CC:C	acceptor_gain	1.0000
17:61869988:CCTA:C	acceptor_loss	1.0000

AlphaMissense

7858 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:61869301:A:G	L1045P	1.000
17:61869740:A:C	F1017L	1.000
17:61869740:A:T	F1017L	1.000
17:61869742:A:G	F1017L	1.000
17:61869750:A:G	L1014P	1.000
17:61869774:A:T	I1006N	1.000
17:61869983:A:C	S936R	1.000
17:61869983:A:T	S936R	1.000
17:61869985:T:G	S936R	1.000
17:61877918:A:G	W817R	1.000
17:61877918:A:T	W817R	1.000
17:61891684:C:A	W576C	1.000
17:61891684:C:G	W576C	1.000
17:61891686:A:G	W576R	1.000
17:61891686:A:T	W576R	1.000
17:61893789:A:C	F566L	1.000
17:61893789:A:T	F566L	1.000
17:61893790:A:G	F566S	1.000
17:61893791:A:G	F566L	1.000
17:61893805:A:G	L561P	1.000
17:61893808:A:G	L560P	1.000
17:61893883:G:T	A535E	1.000
17:61893884:C:G	A535P	1.000
17:61893895:A:T	V531D	1.000
17:61895324:A:C	F526L	1.000
17:61895324:A:T	F526L	1.000
17:61895326:A:G	F526L	1.000
17:61897536:G:T	A484D	1.000
17:61897708:A:G	W455R	1.000
17:61897708:A:T	W455R	1.000

dbSNP variants (sampled 300 via entrez): RS1000107733 (17:61927177 G>A), RS1000109048 (17:61901735 C>A,T), RS1000145604 (17:61908150 C>G), RS1000198683 (17:61907907 C>T), RS1000260376 (17:61895775 C>G,T), RS1000311570 (17:61881631 A>C), RS1000343646 (17:61881363 G>A,C), RS1000526561 (17:61888577 G>A), RS1000536066 (17:61906260 C>T), RS1000599453 (17:61897332 T>A,C), RS1000644056 (17:61883225 C>T), RS1000834763 (17:61920636 G>A), RS1000846445 (17:61918250 T>C), RS1000853646 (17:61877267 G>A,T), RS1000859091 (17:61901570 A>C)

Disease associations

OMIM: gene MIM:611346 | disease phenotypes: MIM:258040

GenCC curated gene-disease

Mondo (1): exstrophy-epispadias complex (MONDO:0017919)

Orphanet (2): Exstrophy-epispadias complex (Orphanet:322), Cloacal exstrophy (Orphanet:93929)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002397_582	Mean spheric corpuscular volume	4.000000e-12

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	affects expression, increases methylation	3
Hydrogen Peroxide	affects expression	2
Cyclosporine	decreases expression	2
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
salinomycin	decreases expression	1
manganese chloride	increases abundance, increases expression	1
nickel sulfate	increases expression	1
beta-methylcholine	affects expression	1
cyanoginosin LR	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Carbamazepine	affects expression	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Manganese	increases abundance, increases expression	1
Ozone	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Acrylamide	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

2 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04760028	PHASE4	COMPLETED	Study on the Influencing Factors of Electroencephalogram Parameters Under Anesthesia
NCT06106425	Not specified	UNKNOWN	Diagnostic and Prognostic Criteria of EEG in Neonatal Convulsions at Assiut University Children Hospital